Full Text View
Tabular View
No Study Results Posted
Related Studies
XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema
This study has been withdrawn prior to recruitment.
( Alternate study projected to assess imaging endpoints versus clinical endpoints. )
Study NCT00226668   Information provided by Celtic Pharma Development Services
First Received: September 23, 2005   Last Updated: December 27, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Brain Edema
Brain Tumor
Additional conditions recognized in this trial
Brain Neoplasms
Edema
More general conditions related to this trial
Brain Diseases
Central Nervous System Diseases
Central Nervous System Neoplasms
Neoplasms
Neoplasms by Site
Nervous System Diseases
Nervous System Neoplasms
Signs and Symptoms
Interventions listed in this trial
hCRF
placebo hCRF
Additional drug interventions recognized in this trial
Corticotropin-Releasing Hormone
Dexamethasone
Dexamethasone acetate
More general drug interventions related to this trial
Anti-Inflammatory Agents
Antiemetics
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Autonomic Agents
Central Nervous System Agents
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Celtic Pharma Development Services
Neurobiological Technologies


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services